204 related articles for article (PubMed ID: 31393868)
21. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
22. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
Rao PG; Lambert GS; Upadhyay C
J Virol; 2023 Sep; 97(9):e0071023. PubMed ID: 37681958
[TBL] [Abstract][Full Text] [Related]
23. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.
Gaudinski MR; Houser KV; Doria-Rose NA; Chen GL; Rothwell RSS; Berkowitz N; Costner P; Holman LA; Gordon IJ; Hendel CS; Kaltovich F; Conan-Cibotti M; Gomez Lorenzo M; Carter C; Sitar S; Carlton K; Gall J; Laurencot C; Lin BC; Bailer RT; McDermott AB; Ko SY; Pegu A; Kwon YD; Kwong PD; Namboodiri AM; Pandey JP; Schwartz R; Arnold F; Hu Z; Zhang L; Huang Y; Koup RA; Capparelli EV; Graham BS; Mascola JR; Ledgerwood JE;
Lancet HIV; 2019 Oct; 6(10):e667-e679. PubMed ID: 31473167
[TBL] [Abstract][Full Text] [Related]
24. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.
Ledgerwood JE; Coates EE; Yamshchikov G; Saunders JG; Holman L; Enama ME; DeZure A; Lynch RM; Gordon I; Plummer S; Hendel CS; Pegu A; Conan-Cibotti M; Sitar S; Bailer RT; Narpala S; McDermott A; Louder M; O'Dell S; Mohan S; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Mascola JR; Graham BS;
Clin Exp Immunol; 2015 Dec; 182(3):289-301. PubMed ID: 26332605
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.
Moldt B; Parvangada A; Martin R; Pace C; Balakrishnan M; Thomsen ND; E Collins S; Kuster H; Braun DL; Günthard HF; Geleziunas R; Callebaut C
J Acquir Immune Defic Syndr; 2021 Sep; 88(1):61-69. PubMed ID: 34397744
[TBL] [Abstract][Full Text] [Related]
26. A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings.
Mgodi NM; Takuva S; Edupuganti S; Karuna S; Andrew P; Lazarus E; Garnett P; Shava E; Mukwekwerere PG; Kochar N; Marshall K; Rudnicki E; Juraska M; Anderson M; Karg C; Tindale I; Greene E; Luthuli N; Baepanye K; Hural J; Gomez Lorenzo MM; Burns D; Miner MD; Ledgerwood J; Mascola JR; Donnell D; Cohen MS; Corey L;
J Acquir Immune Defic Syndr; 2021 May; 87(1):680-687. PubMed ID: 33587510
[TBL] [Abstract][Full Text] [Related]
27. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
28. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting
Magyarics Z; Leslie F; Bartko J; Rouha H; Luperchio S; Schörgenhofer C; Schwameis M; Derhaschnig U; Lagler H; Stiebellehner L; Firbas C; Weber S; Campanaro E; Jilma B; Nagy E; Stevens C
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138568
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
[TBL] [Abstract][Full Text] [Related]
30. Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies.
Bharadwaj P; Riekofski C; Lin S; Seaman MS; Garber DA; Montefiori D; Sarzotti-Kelsoe M; Ackerman ME; Weiner JA
J Immunol Methods; 2020 Apr; 479():112764. PubMed ID: 32070674
[TBL] [Abstract][Full Text] [Related]
31. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
[TBL] [Abstract][Full Text] [Related]
32. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
[TBL] [Abstract][Full Text] [Related]
33. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
[TBL] [Abstract][Full Text] [Related]
34. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
Corey L; Gilbert PB; Juraska M; Montefiori DC; Morris L; Karuna ST; Edupuganti S; Mgodi NM; deCamp AC; Rudnicki E; Huang Y; Gonzales P; Cabello R; Orrell C; Lama JR; Laher F; Lazarus EM; Sanchez J; Frank I; Hinojosa J; Sobieszczyk ME; Marshall KE; Mukwekwerere PG; Makhema J; Baden LR; Mullins JI; Williamson C; Hural J; McElrath MJ; Bentley C; Takuva S; Gomez Lorenzo MM; Burns DN; Espy N; Randhawa AK; Kochar N; Piwowar-Manning E; Donnell DJ; Sista N; Andrew P; Kublin JG; Gray G; Ledgerwood JE; Mascola JR; Cohen MS;
N Engl J Med; 2021 Mar; 384(11):1003-1014. PubMed ID: 33730454
[TBL] [Abstract][Full Text] [Related]
35. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F
PLoS One; 2015; 10(5):e0125954. PubMed ID: 25961283
[TBL] [Abstract][Full Text] [Related]
36. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.
Priddy FH; Lewis DJM; Gelderblom HC; Hassanin H; Streatfield C; LaBranche C; Hare J; Cox JH; Dally L; Bendel D; Montefiori D; Sayeed E; Ackland J; Gilmour J; Schnepp BC; Wright JF; Johnson P
Lancet HIV; 2019 Apr; 6(4):e230-e239. PubMed ID: 30885692
[TBL] [Abstract][Full Text] [Related]
37. Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges.
Liu ZJ; Bai J; Liu FL; Zhang XY; Wang JZ
Int Immunopharmacol; 2017 Nov; 52():44-50. PubMed ID: 28858725
[TBL] [Abstract][Full Text] [Related]
38. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
Lee MJ; Collins S; Babalis D; Johnson N; Falaschetti E; Prevost AT; Ashraf A; Jacob M; Cole T; Hurley L; Pace M; Ogbe A; Khan M; Zacharopoulou P; Brown H; Sutherland E; Box H; Fox J; Deeks S; Horowitz J; Nussenzweig MC; Caskey M; Frater J; Fidler S
Trials; 2022 Apr; 23(1):263. PubMed ID: 35382844
[TBL] [Abstract][Full Text] [Related]
39. Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression.
Martinez-Navio JM; Fuchs SP; Pantry SN; Lauer WA; Duggan NN; Keele BF; Rakasz EG; Gao G; Lifson JD; Desrosiers RC
Immunity; 2019 Mar; 50(3):567-575.e5. PubMed ID: 30850342
[TBL] [Abstract][Full Text] [Related]
40. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
